Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5275690
Max Phase: Preclinical
Molecular Formula: C19H22N2O4
Molecular Weight: 342.40
Associated Items:
ID: ALA5275690
Max Phase: Preclinical
Molecular Formula: C19H22N2O4
Molecular Weight: 342.40
Associated Items:
Canonical SMILES: CCOC(=O)c1nc(C)c2[nH]c3cc(OC)c(OC)cc3c2c1CC
Standard InChI: InChI=1S/C19H22N2O4/c1-6-11-16-12-8-14(23-4)15(24-5)9-13(12)21-17(16)10(3)20-18(11)19(22)25-7-2/h8-9,21H,6-7H2,1-5H3
Standard InChI Key: YIJHOBQVCMYCNA-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 342.40 | Molecular Weight (Monoisotopic): 342.1580 | AlogP: 3.78 | #Rotatable Bonds: 5 |
Polar Surface Area: 73.44 | Molecular Species: NEUTRAL | HBA: 5 | HBD: 1 |
#RO5 Violations: 0 | HBA (Lipinski): 6 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 12.36 | CX Basic pKa: 3.79 | CX LogP: 3.19 | CX LogD: 3.19 |
Aromatic Rings: 3 | Heavy Atoms: 25 | QED Weighted: 0.71 | Np Likeness Score: 0.02 |
1. Beato A, Gori A, Boucherle B, Peuchmaur M, Haudecoeur R.. (2021) β-Carboline as a Privileged Scaffold for Multitarget Strategies in Alzheimer's Disease Therapy., 64 (3.0): [PMID:33528252] [10.1021/acs.jmedchem.0c01887] |
Source(1):